Lung cancer treatment surgery is often an important option for patients with early-stage disease. However, not every patient can safely undergo an operation because of age, reduced lung function, heart disease, tumour location or other medical concerns. In carefully selected cases, CyberKnife S7 may provide a highly precise, non-invasive radiation treatment alternative.
CyberKnife S7 uses robotic stereotactic body radiation therapy, also called SBRT, to deliver focused radiation to lung tumours while accounting for movement caused by breathing. At Valentis Cancer Hospital, treatment planning is designed around the tumour’s size, location, movement and the patient’s overall health.
Understanding Lung Cancer Treatment Options
Lung cancer is not one disease. Treatment depends on the cancer type, stage, tumour location, lymph-node involvement, molecular findings and the patient’s fitness for treatment.
For early-stage non-small cell lung cancer, lung cancer treatment surgery may involve removing the tumour along with a small portion of lung tissue, a lobe or, less commonly, a larger section of the lung. Surgery can be curative for suitable patients, especially when the cancer has not spread beyond the lung.
However, surgery is not always possible. Some patients may have severe chronic obstructive pulmonary disease, poor lung capacity, heart disease or other health conditions that increase anaesthetic and surgical risks. In such situations, a multidisciplinary cancer team may discuss stereotactic body radiation therapy as an alternative local treatment.
CyberKnife is a specialised SBRT platform that is routinely used for early-stage, inoperable non-small cell lung cancer, as well as selected lung metastases and tumours in anatomically challenging locations.
What Is CyberKnife S7?
CyberKnife S7 is an advanced robotic radiation therapy system. It delivers multiple high-dose radiation beams from different angles, concentrating the treatment dose on the tumour while reducing exposure to nearby healthy tissues.
The lungs move continuously as a person breathes, which makes precision especially important. CyberKnife S7 uses image guidance and motion-tracking technology to follow the tumour’s movement during treatment. This allows the radiation beam to remain aligned with the target rather than treating a larger surrounding area simply to compensate for breathing motion.
Accuray describes the CyberKnife platform as providing real-time target tracking and motion-synchronised robotic treatment delivery. Depending on the prescribed plan, treatment may be delivered in a small number of sessions, sometimes in as little as 15 minutes per session.
Unlike lung cancer treatment surgery, CyberKnife does not involve an incision, removal of lung tissue or general anaesthesia in the usual treatment process. It is an outpatient radiation procedure, but it should not be viewed as a replacement for surgery in every case.
Who May Benefit from CyberKnife S7?
CyberKnife S7 may be considered for selected patients after detailed clinical assessment. The technology is especially relevant when the aim is to treat a defined lung lesion accurately while preserving as much healthy lung tissue as possible.
Patients who may benefit include:
- People with early-stage non-small cell lung cancer who are medically unfit for surgery.
- Patients with limited lung function or severe COPD that makes an operation high risk.
- Older adults with multiple medical conditions that increase surgical or anaesthetic risk.
- Individuals who decline surgery after understanding the potential benefits and limitations of all available treatment choices.
- Patients with a small, well-defined lung tumour that moves with breathing.
- Patients with isolated or limited lung metastases, known as oligometastatic disease, where focused local treatment may be clinically appropriate.
- Patients with recurrent lung tumours or those requiring carefully planned re-treatment after earlier radiation.
Evidence supports SBRT as a potentially curative treatment for medically inoperable patients with stage I non-small cell lung cancer. A clinical review of CyberKnife-based stereotactic radiotherapy notes that SBRT is a curative option for patients who cannot undergo surgery or choose not to have surgery.
CyberKnife may also be considered for tumours located close to sensitive structures, including the chest wall or central areas of the lung, where a highly conformal radiation plan can be valuable.
Benefits of CyberKnife S7 for Lung Tumours
The possible benefits of CyberKnife S7 include:
- Non-invasive treatment with no surgical incision.
- No removal of lung tissue.
- No general anaesthesia in typical treatment pathways.
- Real-time tracking of tumour movement during breathing.
- Focused radiation delivery to protect surrounding healthy tissue.
- Shorter treatment courses than many conventional radiation schedules.
- Outpatient treatment for many patients.
- A potential option for people who cannot undergo lung cancer treatment surgery.
The robotic arm and image-guidance technology are designed to adapt beam delivery to tumour movement throughout a session. This is particularly significant for lung tumours because even small changes in breathing position can affect treatment accuracy.
For patients with severe pulmonary dysfunction, small clinical studies have reported that CyberKnife SBRT can be effective and well tolerated in selected early-stage lung cancer cases. However, individual results can vary, and treatment decisions require specialist evaluation.
Important Limitations and Risks
CyberKnife S7 is not suitable for every lung cancer diagnosis. It may not be the best option when cancer has spread extensively, there are multiple untreated sites of disease or the tumour is too large or close to critical structures for safe dose delivery.
Possible side effects may include fatigue, cough, temporary chest discomfort, shortness of breath, inflammation of the lung tissue and, less commonly, radiation-related injury to nearby structures. The risk depends on the tumour’s location, size, prior radiation exposure and the patient’s baseline lung health.
Patients also need regular scans after treatment. Radiation does not remove the tumour immediately; instead, it damages cancer cells over time. Follow-up imaging helps doctors evaluate treatment response and identify any recurrence or changes in the lungs.
Choosing the Right Cancer Centre
When comparing options for a lung cancer best hospital in India, patients should look beyond the availability of advanced equipment. A strong treatment decision requires experienced radiation oncologists, medical oncologists, thoracic surgeons, pulmonologists, radiologists and support teams working together.
A best cancer hospital in India should offer:
- Accurate diagnostic imaging and staging.
- Histopathology and molecular testing where indicated.
- Multidisciplinary tumour-board review.
- Personalised radiation planning.
- Access to surgery, systemic therapy and supportive care.
- Long-term follow-up after treatment.
At Valentis Cancer Hospital, CyberKnife S7 can be considered as part of an integrated treatment pathway rather than as a one-size-fits-all solution. For some patients, lung cancer treatment surgery remains the preferred approach. For others—particularly those who are medically inoperable or have high surgical risk, CyberKnife S7 may provide an advanced, precise and non-invasive treatment option.
